Financial Results - TriSalus Life Sciences, Inc. announced preliminary unaudited financial results for Q4 2025 and provided revenue guidance for 2026[6] - The press release detailing the financial results was issued on January 12, 2026[6] - The financial results and guidance are not deemed "filed" under the Securities Exchange Act of 1934[7] Company Information - The company is listed on the Nasdaq Global Market under the trading symbol TLSI[4] - The company operates from its principal executive office located in Westminster, Colorado[2] - The company is classified as an emerging growth company[5] Stock and Warrants - The common stock has a par value of $0.0001[4] - The warrants are exercisable for one share of common stock at an exercise price of $11.50 per share[4] Compliance and Reporting - The company has not elected to use the extended transition period for complying with new financial accounting standards[5] - The report was signed by Chief Financial Officer David Patience[12]
MEDTECH ACQUISIT(MTAC) - 2025 Q4 - Annual Results